A Fagiolini1, E Aguglia2, A Ballerini3, G Callista4, B Carpiniello5, M Clerici6, G Corrivetti7, P De Fazio8, S De Filippis9, S De Giorgi10, G Favaretto11, E Ferri12, G Gargiulo13, M G Giustra14, D La Barbera15, G Maina16, C Mencacci17, G Montagnani18, A Panariello19, G Pigato20, A Tortorella21, L Vernacotola14, A Vita22. 1. University of Siena, Italy. Electronic address: andreafagiolini@gmail.com. 2. University of Catania, Italy. 3. U Sod di Psichiatria, AOU Careggi Firenze, Italy. 4. UOSD S.P.D.C. P.O. Giulianova Asl Teramo, Italy. 5. University of Cagliari, Italy. 6. University of Milano Bicocca, Italy. 7. ASL Salerno, EBRIS foundation, Italy. 8. University Magna Graecia, Catanzaro, Italy. 9. Neuropsychiatric clinic villa von Siebenthal-Rome, Italy. 10. Department of Mental Health, ASL Lecce, Italy. 11. Department of Mental Health, Ulss2 Marca Trevigiana, Italy. 12. ASL Roma 6, Rome, Italy. 13. Area Vasta2, Ancona-A.S.U.R.Marche, Italy. 14. Otsuka Pharmaceuticals, Italy. 15. University of Palermo, Italy. 16. University of Torino, Italy. 17. DSMD - Neuroscienze Asst Fatebenefratelli- Sacco, Milano, Italy. 18. Lundbeck, Italy. 19. ASST G.O.M. Niguard, Milano, Italy. 20. University of Padova Medical Center, Italy. 21. University of Perugia, Italy. 22. University of Brescia, Italy.
Abstract
OBJECTIVES: To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. METHODS: Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. RESULTS: Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5; 3) psychotic spectrum schizoid score ≤ 11. CONCLUSIONS: A relatively high number of patients (n = 225, 86%) were persistent to A-LAI for at least 6 months. Not surprisingly, very severe patients were more unlikely to be persistent. However, it is noteworthy that a large number of subjects with high CGI score at the time when A-LAI was started (82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7) were persistent. Larger, controlled, prospective and longer studies are warranted.
OBJECTIVES: To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. METHODS: Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. RESULTS: Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5; 3) psychotic spectrum schizoid score ≤ 11. CONCLUSIONS: A relatively high number of patients (n = 225, 86%) were persistent to A-LAI for at least 6 months. Not surprisingly, very severe patients were more unlikely to be persistent. However, it is noteworthy that a large number of subjects with high CGI score at the time when A-LAI was started (82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7) were persistent. Larger, controlled, prospective and longer studies are warranted.
Authors: Andrea Fagiolini; Eugenio Aguglia; Andrea Ballerini; Gaetano Callista; Bernardo Carpiniello; Massimo Clerici; Giulio Corrivetti; Alessandro Cuomo; Pasquale De Fazio; Sergio De Filippis; Serafino De Giorgi; Arianna Goracci; Daniele La Barbera; Claudio Mencacci; Gino Montagnani; Giorgio Pigato; Jarno Vannucchi; Antonio Vita Journal: Ann Gen Psychiatry Date: 2022-09-29 Impact factor: 3.301
Authors: Daniel Schöttle; Wolfgang Janetzky; Daniel Luedecke; Elmar Beck; Christoph U Correll; Klaus Wiedemann Journal: BMC Psychiatry Date: 2020-02-22 Impact factor: 3.630